Chalkidou Anna, Oikonomou Efthimios, Lambrinos Dimitrios, Bothou Anastasia, Kyriakou Dimitrios, Nikolettos Konstantinos, Marinos Georgios, Iatrakis Georgios, Zervoudis Stefanos, Nikolettos Nikolaos, Tsikouras Panagiotis
Department of Obstetrics and Gynecology,Democritus Univesity of Thrace, Greece.
Neonatal Intensive Care Unit of University Hospital Alexandroupolis, Greece.
Mater Sociomed. 2023 Sep;35(3):206-214. doi: 10.5455/msm.2023.35.206-214.
Menopause is characterized by a series of symptoms and effects from the various systems and organs, for which, the decline in estrogen production from the ovaries is considered responsible.
The aim of this study was to make comparative study of the administration of the combination preparation of isoflavones and hyaluronic acid in menopausal women for the treatment of the symptoms of menopause, urogenital atrophy and osteoporosis in relation to existing hormone replacement therapies.
In this five-year, double-blind, placebo-controlled clinical study, a total of 274 postmenopausal women were enrolled and classified into three groups. Participants in group A, were 96 women who did not receive Hormone Replacement Therapy (HRT), in the second group, 92 received daily treatment with tibolone (2.5 mg) as monotherapy, and in the third group, 86 received treatment with a pharmaceutical formulation of hyaluronic acid 120 mg and isoflavones. MF11RCE 80 mg.
In the postmenopausal women of our study, a significant reduction of postmenopausal symptoms was found in both groups B and C of participants who received hormone replacement preparations compared to group A who did not receive HRT. Furthermore, no difference in efficacy was observed between the administered preparations of isoflavones and tibolone.
The combination of isoflavones and hyaluronic acid has the same efficacy as tibolone in menopausal symptoms.
更年期的特征是出现一系列症状以及各个系统和器官产生的影响,人们认为这是卵巢雌激素分泌减少所致。
本研究旨在比较异黄酮与透明质酸联合制剂对更年期女性更年期症状、泌尿生殖系统萎缩和骨质疏松的治疗效果,并与现有的激素替代疗法进行对比。
在这项为期五年的双盲、安慰剂对照临床研究中,共招募了274名绝经后女性并将其分为三组。A组有96名未接受激素替代疗法(HRT)的女性,第二组有92名女性每日接受替勃龙(2.5毫克)单一疗法治疗,第三组有86名女性接受含120毫克透明质酸和80毫克MF11RCE异黄酮的药物制剂治疗。
在我们研究的绝经后女性中,与未接受HRT的A组相比,接受激素替代制剂的B组和C组参与者的更年期症状均显著减轻。此外,所给予的异黄酮制剂和替勃龙在疗效上未观察到差异。
异黄酮与透明质酸联合制剂在治疗更年期症状方面与替勃龙具有相同疗效。